Categories

2022-2023 EVENTS



2022 Events

28 Aug - 01 Sep 2022
The International Surgical Week (ISW)
Kuala Lumpur

31 Aug – 2 Sept 2022
Medical Fair Asia
Marina Bay Sands, Singapore

3-9 September
Medical Fair Asia
Digital, Online

9-10 September 2022
World Pediatrics Conference
Bangkok, Thailand

9-10 September 2022
World Heart and Cardiothoracic Surgery Conference
Bangkok, Thailand

19-21 September 2022
23rd SE-Asian Healthcare & Pharma Show
Kuala Lumpur

27-29 September 2022
Smart Healthcare Expo (Health Malaysia)
MITEC

27-29 September 2022
Asia Pandemic Congress
Kuala Lumpur Convention Centre

19-20 September 2022
23nd Global Nursing Education Conference
Brisbane, Australia

30 Sep - 2 Oct 2022
Malaysia International Dental Show (MIDS)
Sunway Pyramid Convention Centre, Subang Jaya, Malaysia

7-9 November 2022
Saudi International MedLab Expo
Riyadh International Convention and Exhibition Center

7-9 November 2022
Saudi International Pharma Expo
Riyadh International Convention and Exhibition Center

11-13 November 2022
Eldercare Exhibition and Conference Asia (ELDEX Asia 2022)
Suntex Singapore Exhibition and Convention Centre

14-15 November 2022
Healthcare Asia Pacific
Osaka, Japan

2023 Events

30 May – 1 June 2023
APHM
KL Convention Centre, Kuala Lumpur

13-15 September 2023
Medical Fair Thailand
BITEC, Bangkok


Free counters!

Health DG

Anticoagulant medication Dabigatran Etexilate Capsules USP 75 mg and 150 mg are not registered in Malaysia, says Health Director-General Tan Sri Dr Noor Hisham Abdullah (pix).

He said the Ministry of Health (MOH) had checked the registered products database of the National Pharmaceutical Regulatory Agency (NPRA) to confirm the matter following an article published on the medscape.com website titled ‘Dabigatran Recalled Over Potential Carcinogen’ on March 23.

The article reported that Ascend Laboratories LLC carried out a consumer-level recall of the product following the detection of nitrosamine impurity ‘N-nitroso-dabigatran’ which exceeded the global Acceptable Daily Intake (ADI) level.

“Dabigatran Etexilate Capsules USP 75 mg and 150 mg are not registered in Malaysia.

“As a reminder, products that are not registered through the Drug Control Authority (DCA) are not allowed to be marketed in Malaysia,“ said Dr Noor Hisham in a statement today.

He said the products were oral anticoagulants used to reduce the risk of stroke and blood clots.

According to him, nitrosamine impurities were commonly found in water and food, including cured and grilled meats, dairy products and vegetables.

“Exposure to nitrosamines that exceed the ADI level in the long term has the potential to increase the risk of cancer among consumers,“ he said, adding that the NPRA was continuously monitoring medical products to ensure their quality, safety and effectiveness. – Bernama